Author:
GABUNIA LUIZA,GHONGHADZE MANANA,GORGADZE GIGI,VARAZI GIORGI,KIKVADZE NINO,TVALABEISHVILI ANA,FILIPETS NATALIA,RUKHADZE LONDA
Publisher
Association For Science (Publications)
Reference10 articles.
1. 1. McQueenie R, Foster HME, Jani BD, Katikireddi SV, Sattar N, Pell JP, Ho FK, Niedzwiedz CL, Hastie CE, Anderson J, et al. Multimorbidity, polypharmacy, and COVID-19 infection within the UK Biobank cohort. PLoS ONE. 2020;15(8): e0238091.
2. 2. loanusi S, Mgbere O, Essien EJ. Polypharmacy among COVID-19 patients: a systematic review. J Am Pharm Assoc JAPhA. 2021;61(5):e14–25.
3. 3. Potempski F, Bilimoria K: Polypharmacy in the age of COVID-19: medication management during a pandemic. University of Toronto Medical Journal 2021, 98(1):73-5.
4. 4. Gutierrez-Valencia M, Izquierdo M, Cesari M, Casas-Herrero A, Inzitari M, Martinez-Velilla N. The relationship between frailty and polypharmacy in older people: a systematic review. Br J Clin Pharmacol. 2018;84(7):1432–44.
5. 5. Pazan F, Wehling M. Polypharmacy in older adults: a narrative review of definitions, epidemiology and consequences. Eur Geriatr Med. 2021;12(3):443–52.